# A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease

> **NCT04084483** · PHASE2 · COMPLETED · sponsor: **Kowa Research Institute, Inc.** · enrollment: 238 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** K-161
- **OTHER:** Placebo (Vehicle)

## Key facts

- **NCT ID:** NCT04084483
- **Lead sponsor:** Kowa Research Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-04
- **Primary completion:** 2020-01-09
- **Final completion:** 2020-01-09
- **Target enrollment:** 238 (ACTUAL)
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04084483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04084483, "A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04084483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*